Category: Trial Initiations & biotech partnerships
Opportunity: Trial initiations & drug delivery device/Sub-Q partner(s)
Company: Viridian Therapeutics
Product/Asset: VRDN-001
Latest trigger event for Opp: PR July 10, 2023
Target Companies: CROs, Clinical trial recruitment companies, SubQ technology companies
Details:
Viridian plans to initiate a Phase 3 trial (THRIVE-2) of VRDN-001 in patients with chronic thyroid eye disease (TED) in the third quarter of 2023. In addition, Viridian plans to initiate Phase 1 trials of VRDN-003 and VRDN-001 SC in healthy volunteers in the third quarter of 2023. By the end of 2023, Viridian expects to select its lead subcutaneous program and advance the program into a pivotal Phase 2/3 trial in the middle of 2024. Also, Viridian is currently looking to Initiate a pen device supply agreement with an experienced drug delivery device manufacturer in the second half of 2023. Thus, CROs and drug delivery companies have an immediate opportunity to partner with Viridian for these upcoming events.
About Viridian Therapeutics
Company Type: Public Company
Market Cap (7/21/23): ~$900M
Location: Waltham, Massachusetts
Cash (Q1 2023): ~$375M
Burn rate/quarter: ~$-35M
Technology Focus: Monoclonal antibody
Latest stage asset: Phase 3
Indications: Rare diseases, Thyroid eye disease
Key employees: Subscribe to learn more!
💡 Do you sell your products or services to biopharma companies? 💡
BiopharmIQ MarketCompass is a market intelligence tool to help with your business development. Get a free sample report of potential targets.
Article History:
Originally posted 7/21/23 (RB)
Comments